🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Spero Therapeutics, Inc. (SPRO)
NASDAQ: SPRO · Real-Time Price · USD
0.8768
-0.0245 (-2.72%)
Nov 18, 2026, 1:12 PM EST - Market open

Spero Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
41.5666.847.98103.7853.5118.26
Revenue Growth
2.48%39.24%-53.77%93.95%193.10%95.67%
Cost of Revenue
38.4738.4796.7651.4447.5964.53
Gross Profit
3.0928.34-48.7852.345.92-46.27
Selling, General & Admin
19.421.1823.725.5536.4841.7
Operating Expenses
-3.9421.1823.725.5536.4841.7
Operating Income
7.037.16-72.4826.79-30.57-87.97
Interest Expense
-----2.61-1.94
Interest & Investment Income
2.512.514.743.941.110.35
Other Non Operating Income (Expenses)
-3.790.010.06-0.010.86-0.19
EBT Excluding Unusual Items
5.759.68-67.6930.71-31.2-89.76
Merger & Restructuring Charges
--0.26-0.88--11.63-
Asset Writedown
--0.59--5.31--
Other Unusual Items
-----3.58-
Pretax Income
-29.258.83-68.5725.4-46.42-89.76
Income Tax Expense
0.260.26-2.6--
Earnings From Continuing Operations
-29.518.57-68.5722.81-46.42-89.76
Net Income
-29.518.57-68.5722.81-46.42-89.76
Net Income to Common
-29.518.57-68.5722.81-46.42-89.76
Net Income Growth
------
Shares Outstanding (Basic)
575654533831
Shares Outstanding (Diluted)
575954533831
Shares Change
3.52%9.25%1.98%40.98%21.65%38.01%
EPS (Basic)
-0.510.15-1.270.43-1.23-2.91
EPS (Diluted)
-0.510.15-1.270.43-1.23-2.91
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
--12.62-23.44-33-7.73-64.35
Free Cash Flow Per Share
--0.21-0.43-0.62-0.21-2.08
Gross Margin
7.43%42.42%-101.67%50.43%11.06%-253.45%
Operating Margin
16.91%10.72%-151.08%25.81%-57.13%-481.87%
Profit Margin
-71.02%12.83%-142.91%21.98%-86.74%-491.65%
Free Cash Flow Margin
--18.90%-48.86%-31.79%-14.45%-352.47%
EBITDA
-7.16-72.4827.15-29.7-87.33
EBITDA Margin
-10.72%-151.08%26.16%-55.50%-
D&A For EBITDA
-000.370.870.65
EBIT
7.037.16-72.4826.79-30.57-87.97
EBIT Margin
16.91%10.72%-151.08%25.81%-57.13%-
Effective Tax Rate
-2.96%-10.23%--
Revenue as Reported
41.5666.847.98103.7853.5118.26
SEC Filings: 10-K · 10-Q